EcoDrugPlus

Glutamate Receptor Ionotropic, Nmda 3b-Like

Ensembl ID : ENSHBUG00000015352
Gene Symbol: LOC102310445
2 Cross references
226 Possible Orthologues:

Glutaminase

Ensembl ID : ENSHBUG00000009819
Gene Symbol: GLS
3 Cross references
230 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSHBUG00000023387
Gene Symbol: LOC102312459
2 Cross references
232 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSHBUG00000017570
Gene Symbol: GSK3A
3 Cross references
186 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSHBUG00000003773
Gene Symbol: GSK3B
3 Cross references
222 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSHBUG00000016155
Gene Symbol: LOC102289874
3 Cross references
187 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSHBUG00000009970
Gene Symbol: LOC102299719
2 Cross references
153 Possible Orthologues:

Granzyme B-Like

Ensembl ID : ENSHBUG00000000261
Gene Symbol: LOC102310726
2 Cross references
949 Possible Orthologues:

Granzyme B-Like

Ensembl ID : ENSHBUG00000010202
Gene Symbol: LOC102310421
2 Cross references
949 Possible Orthologues:

Granzyme B-Like

Ensembl ID : ENSHBUG00000008623
Gene Symbol: LOC102304448
2 Cross references
951 Possible Orthologues:

Granzyme G-Like

Ensembl ID : ENSHBUG00000010276
Gene Symbol: LOC102309900
2 Cross references
921 Possible Orthologues:

Group 10 Secretory Phospholipase A2-Like

Ensembl ID : ENSHBUG00000003143
Gene Symbol: LOC102313624
3 Cross references
232 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).